Ibuprofen-induced liver mitochondrial permeability transition

Toxicology Letters

Volumn 111, Issue 3, 2000, Pages 213-218

  Al Nasser, Ibrahim A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cyclosporin A; Hepatotoxicity; Ibuprofen; Mitochondria

Indexed keywords

ARSENAZO 3; CALCIUM ION; CYCLOSPORIN A; IBUPROFEN; PHOSPHATE; ROTENONE; TETRAPHENYLPHOSPHONIUM;

ANIMAL TISSUE; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG EFFECT; LIVER MITOCHONDRION; LIVER TOXICITY; MALE; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION SWELLING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM; CYCLOSPORINE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENTS; INDICATORS AND REAGENTS; MALE; MEMBRANE POTENTIALS; MITOCHONDRIA, LIVER; MITOCHONDRIAL SWELLING; ONIUM COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0033989630     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00180-0     Document Type: Article

References (29)

1. Adams S.S., Bough R.G., Cliffe E.E. et al. Some aspects of the pharmacology, metabolism and toxicology of ibuprofen. Rheumatoid. Phys. Med. Suppl. 9:1970;9-26.
2. Al-Nasser I., Campbell P. Cyclosporin A inhibition of phosphate-induced calcium release from rat kidney cortex mitochondria. Med. Sci. Res. 21:1993;777-779.
3. 2+-induced permeabilisation of rat liver mitochondria. Biochem. J. 239:1986;19-24.
4. Al-Nasser I. Salicylate-induced kidney mitochondrial permeability transition is prevented by cyclosporin A. Toxol. Lett. 105(1):1999;1-8.
5. 2+-activated inner membrane pore of heart mitochondria. Eur. J. Biochem. 230:1995;1125-1131.
6. Bernardi P., Petronili V. The permeability transition pore as a mitochondria calcium release channel. A critical appraisal. J. Bioenerg. Biomemb. 24:1996;77-90.
7. Busson M. Update on ibuprofen (review article). J. Int. Med. Res. 14:1986;53-62.
8. Castillo M., Lam F., Dooley M.A. et al. Disposition and covalent binding of ibuprofen and its acylglucuronide in the elderly. Clin. Pharmacol. Ther. 57:1995;636-644.
9. Collier P.S., D'Arcy P.F., Harron D.W., Morrow N. Pharmacokinetic modeling of Ibuprofen. Br. J. Clin. Pharm. 5:1978;528-530.
10. Court H., Streete P.J., Volans G.N. Acute poisoning with ibuprofen. Hum. Toxicol. 2:1983;381-384.
11. 2+ overload. Eur. J. Biochem. 178:1988;489-501.
12. Davies N.M. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clinc. Pharmacokinet. 34(2):1998;101-154.
13. Griffiths E., Halestrap A. Further evidence that cycloporin A protect mitochondria from calcium overload by inhibiting matrix peptidyl-prolyl cis-trans isomerase. Biochem. J. 274:1991;611-614.
14. Halestrap A., Connern C., Griffiths E., Kerr P. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reprefusion injury. Mol. Cell. Biochem. 174:1997;167-172.
15. Halpern S.M., Fitzpalrick R., Volans G.N. Ibuprofen toxicity. A review of adverse reactions and overdose. Adverse Drug React. Toxicol. Rev. 12(2):1993;107-128.
16. Hamman M.A., Thompson G.A., Hall S.D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharmacol. 54:1997;33-41.
17. Kamo N., Muratsugo M., Ruyi H., Kobatake J. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenylphos-phonium and relation between proton electrochemical potential and phosphorylation potential in steady state. J. Membr. Biol. 48:1979;105-121.
18. Kimberly R.P., Sherman R.L., Mouradian J., Lockshin M.D. Apparent acute renal failure associated with therapeutic aspirin and ibuprofen administration. Atthritis. Rheum. 22:1979;281-285.
19. Korger A., Klingenberg M. A modified biuret method for the determination of protein. Biochem. Z. 344:1966;317-338.
20. Mills R.F., Adams S.S., Cliffe E.E. et al. The metabolism of ibuprofen. Xenobiotica. 3:1973;589-598.
21. Nicolli A., Basso E., Petronilli V., Wenger P., Bernardi P. Interaction of cyclophilin with mitochondrial inner membrane and regulation of the permeability transition pore, acyclosporin A-sensitive channel. Biol. Chem. 271:1996;2185-2191.
22. Novgord S., Gudz T. Permeability transition pore of the inner mitochondrial membrane can operate in two open state with different selectivities. J. Bioenerg. Biomembr. 28:1996;139-146.
23. Peng C., Kane J., Slaub K., Murphy M. Improvement of mitochondrial energy production in ischamic myocardium by in vivo infusion of ruthenium red. Cardiovasc. Pharm. 2:1980;45-54.
24. Petit P., Susin S., Zamzami N., Mignote B., Kroemer G. Mitochondria and programmed cell death; back to the future. FEBS Lett. 396:1996;7-13.
25. Salgueiro-Pagadigorria C.L., Kelmer-Bracht A., Bracht A., Ishii-Ikamoto E.L. Effect of the nonsteroidal anti-inflammatory drug piroxicam on rat liver mitochondriaa. Comp. Biochem. Physiol. 113:1996;85-91.
26. Stempel D.A., Miller J.J. Lymphopenia and hepatic toxicity with ibuprofen. J. Pediatr. 90:1977;657-658.
27. Trost L., Lemasters J. Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: implications for Reye's syndrome. Toxol. Appl. Pharmacol. 147:1997;431-441.
28. Vangiessen G.J., Kaisser D.G. Ibuprofen entantiomers in biological specimens. J. Pharm. Sci. 64:1975;798-801.
29. Zoratiti M., Szabo I. The mitochondrial permeability transition. Biochem. Biophys. Acta. 1241:1995;139-176.